Metacognitive therapy (MCT)

Article written and reviewed by Dr Luca Moretti

Metacognitive Therapy (MCT), developed by Adrian Wells, is a transdiagnostic psychotherapy derived from the Self-Regulatory Executive Function model of Wells and Matthews. In treating depression, it does not focus primarily on correcting the content of negative thoughts, but on the processes that prolong their impact: rumination, perseverative attention to threat, control strategies and beliefs about the meaning and regulation of thinking. The term “metacognitive” therefore refers to the knowledge and strategies through which a person evaluates, controls and responds to their own mental activity.

MCT should be distinguished both from cognitive therapy from Beck's model and from other interventions called “metacognitive”, such as metacognitive training used in some psychotic disorders. In Wells' MCT, the central construct is the Cognitive Attentional Syndrome (CAS), a pattern characterized by perseverative thinking, threat monitoring and coping strategies that maintain self focused processing and the sense of losing control over mental activity.

Clinical evidence for MCT in depression is favorable but less extensive than the evidence available for CBT, behavioral activation and IPT. Early meta analyses reported large effects and some favorable comparisons with CBT, but the same authors emphasized small samples and few active controls. Subsequent studies have expanded the evidence base without eliminating the need for caution when describing MCT as definitively superior or equivalent.

Metacognitive model of depression

In the MCT model, the presence of negative thoughts is not sufficient to explain persistence of depression. After an internal or external event, the person may begin to ruminate about the causes, meaning or consequences of their state: “Why do I feel this way?”, “What does this say about me?”, “I will never get out of this”. The problem is not defined by pessimistic content alone, but by the repetitive and difficult to interrupt process that keeps attention focused on distress and diverts resources from action and flexible processing.

Positive metacognitive beliefs may support the initiation of rumination, for example the belief that continuously analyzing one's mood will help understand it, prevent mistakes or finally find a solution. Negative metacognitive beliefs instead concern uncontrollability, dangerousness or the meaning of thinking, such as the belief that rumination cannot be stopped or that having certain thoughts demonstrates mental damage. The two categories can coexist and create a conflict in which the person continues a strategy they consider both useful and dangerous.

The CAS also includes threat monitoring and coping strategies that may maintain the problem. In depression, this may translate into repeated checking of mood, searching for signs of failure, avoidance of emotional information, attempts to suppress thoughts or reassurance seeking behaviors. None of these behaviors is pathological in absolute terms: the formulation evaluates frequency, rigidity, function and consequences.

The therapeutic hypothesis is that modifying the way thinking is regulated reduces time spent ruminating and makes beliefs about uncontrollability less credible. MCT therefore aims to restore the patient's perception that they can choose when to engage in mental processing and when to shift attention. It does not require negative thoughts to be eliminated: the main change concerns the response to thought and the belief system that governs its persistence.

Observational studies and meta analyses of the metacognitive model find associations among metacognitive beliefs, rumination and depressive symptoms. These associations are consistent with the model but do not, by themselves, prove a complete causal sequence. Demonstrating a mechanism requires showing that change in the process precedes and specifically mediates clinical improvement while controlling for alternative explanations.

Assessment and case formulation

Initial assessment must distinguish the psychotherapeutic model from diagnosis. Before formulating the CAS, the depressive presentation, severity, course, functional impairment, suicide risk, possible psychotic or bipolar features, substance use and comorbidities must be defined. MCT does not provide alternative diagnostic criteria and does not replace diagnostic and safety standards in clinical practice.

Metacognitive analysis reconstructs recent episodes of rumination sequentially. The trigger is identified, where attention is directed is observed, repeated questions are identified, duration of processing is assessed, strategies used to control it are examined and consequences are evaluated. This makes it possible to move from global descriptions such as “I think too much” to an operational formulation that can be tested during therapy.

The therapist then explores positive and negative beliefs about rumination. Targeted questions can clarify what the patient believes they gain from ruminating, what they fear would happen if they stopped and how controllable they consider the process to be. The goal is not to prove that the patient is “wrong”, but to create testable hypotheses about the rules that maintain the CAS.

The formulation is shared in an understandable form and updated through experience. A key point is distinguishing the spontaneous occurrence of a thought from voluntarily or semi voluntarily prolonging a chain of processing. This distinction allows attentional control to be tested without demanding total control over the appearance of thoughts, an unrealistic and potentially counterproductive goal.

When cognitive difficulties, trauma, severe anxiety or other conditions are present, the therapist should verify that the model adequately describes the priority process. High rumination does not automatically make MCT the most appropriate treatment because rumination is transdiagnostic and can also be addressed effectively with other psychotherapies.

The formulation can be supported by metacognitive questionnaires and measures of rumination, but these tools should not be used as diagnostic tests or automatic indication thresholds. Their main value is to describe dimensions of the process and monitor change. A high score can arise from different clinical presentations and should be interpreted together with the interview, course and concrete function of perseverative thinking.

Techniques: detached mindfulness, attention and metacognitive beliefs

A characteristic technique is detached mindfulness, which can be translated as detached awareness. The patient learns to notice the appearance of thoughts, images or impulses without responding with prolonged analysis, suppression or attempts to resolve them immediately. “Detached” does not mean emotionally cold or dissociated: it indicates the possibility of observing a mental event without automatically entering the process that amplifies it.

MCT uses experiments to demonstrate that engagement in rumination is more modifiable than the patient believes. The therapist may compare periods in which the patient deliberately prolongs thinking with periods in which they allow the trigger to pass and redirect attention. The goal is to produce a corrective experience regarding controllability, not to impose perfect suppression of thought.

The Attention Training Technique is a structured exercise aimed at developing flexible attentional control through selective focusing, rapid attentional shifts and divided attention across external stimuli. It is not simply a relaxation technique and is not used to demonstrate that the patient should distract themselves from every emotion. The rationale is to reduce rigidity of self focused attention and increase the capacity to choose where attention is directed.

Metacognitive beliefs are modified through Socratic dialogue, review of evidence and behavioral experiments specifically directed at properties of thinking. A belief such as “if I do not ruminate I will never understand the problem” can be tested by comparing days or situations with different amounts of rumination and observing whether effective problem solving improves or worsens. A belief in uncontrollability can be tested through postponement or interruption exercises.

Treatment also includes reducing counterproductive strategies such as continuous mood monitoring, compulsive searching for explanations, thought control and some forms of avoidance. The therapist must nevertheless distinguish these behaviors from adaptive and necessary strategies. A behavior is not eliminated because it “looks metacognitive”, but because functional assessment shows that it maintains the CAS and distress.

The final phase consolidates a new response plan for triggers and addresses relapse risk. The patient learns to recognize return of the CAS as a signal to apply skills rather than automatically interpreting it as proof of an inevitable new depression. This plan should be integrated with broader prevention strategies for depressive disorder.

Clinical evidence in depression

Early depression specific applications of MCT included small studies in recurrent or persistent depression and a platform trial in patients described as treatment resistant. These studies showed substantial improvements but, because of their size and design, should be regarded as preliminary rather than definitive evidence of comparative efficacy.

The 2014 meta analysis by Normann and colleagues included studies of anxiety disorders and depression and reported large pre post effects and favorable results compared with waiting list and CBT. The authors nevertheless specified that comparison with CBT should be interpreted cautiously because of small samples and the limited number of active control conditions. Omitting this warning would overstate the certainty of the evidence.

The 2018 systematic review and meta analysis confirmed an overall favorable picture for MCT on target symptoms, anxiety, depression and metacognitions, but again highlighted the need for more independent, high quality studies. Part of the literature comes from groups closely connected with treatment development, a common situation during early validation of a psychotherapy but relevant to generalizability.

Subsequent depression trials have added to the evidence, but the body of studies remains smaller than that for CBT. Network meta analyses comparing major psychotherapies often do not have enough MCT studies to produce equally robust estimates. It is therefore more accurate to describe MCT as a promising approach with empirical support, avoiding claims of established superiority for major depression.

Major international guidelines for depression do not uniformly place MCT among named first line interventions. This is not equivalent to a judgment of inefficacy: it also reflects methodological thresholds, update dates and availability of studies. Clinically, when MCT is proposed, the patient should receive balanced information about the level of evidence and established alternatives.

Indications, safety and relationship with other approaches

MCT may be particularly consistent with a formulation in which rumination, worry, internal monitoring and beliefs about uncontrollability play a central role. These elements are not diagnostic criteria and there are no validated thresholds that automatically select MCT over CBT. Patient preference, therapist competence, previous responses and local availability remain important.

Compared with cognitive therapy, MCT more directly modifies the process of thinking and beliefs about its regulation, rather than systematically assessing the truth of each automatic thought. Compared with ACT, it uses a different theory and more explicitly aims to deactivate the CAS and metacognitive beliefs. Superficial technical similarities do not make the models interchangeable.

MCT can be integrated with pharmacotherapy when clinically indicated. Treatment does not authorize reducing or discontinuing antidepressants without medical assessment. In patients with high suicide risk, psychosis, mania, catatonia or severe functional impairment, comprehensive management of safety and illness takes priority and may include more intensive levels of care.

Attention exercises and detached mindfulness should be adapted to patient tolerance. If an exercise significantly increases dissociation, destabilization or distress, it should be reformulated or stopped and the case reassessed. The instruction “do not engage with thoughts” should not become a new form of suppression or a blaming message when rumination persists.

Monitoring should include symptoms, functioning and therapeutic process. Metacognition questionnaires may be useful for formulation and research, but they do not replace clinical assessment of depression and are not diagnostic tests for MCT. An insufficient response requires reassessment of diagnosis, formulation, protocol fidelity and treatment alternatives.

Treatment quality also depends on fidelity to MCT. If the therapist mainly discusses the truth of depressive thoughts, the intervention moves closer to cognitive therapy; if the therapist only invites observation of thoughts without working on CAS and metacognitive beliefs, it may resemble other mindfulness based approaches. This distinction matters both clinically and in research because poorly differentiated protocols make comparative results more difficult to interpret.

Relapse prevention and research perspectives

The rationale for relapse prevention is to help the patient recognize the return of perseverative thinking early without interpreting it as uncontrollable. The plan may include identifying triggers, reducing mood monitoring, detached mindfulness and testing metacognitive beliefs that tend to reactivate under stress. These strategies should be integrated with sleep, treatment adherence, management of comorbidities and the overall clinical plan.

To establish the position of MCT in depression more precisely, large pragmatic trials, independent replications, comparisons with bona fide psychotherapies of equal intensity, mediator analyses and long follow up are needed. Data on costs, therapist training, implementation in services and populations with comorbidities are also important because many early trials use more selected samples than routine clinical practice.

Another area of research concerns mechanism specificity. If reduction of the CAS and metacognitive beliefs reliably precedes improvement and explains a portion of the effect not attributable to common factors, the theoretical rationale for MCT would receive stronger support. Until then, it is appropriate to clearly distinguish observed clinical efficacy from full demonstration of the proposed mechanisms.

Overall, MCT is a structured and theoretically coherent approach with promising clinical results in depression and other emotional disorders. A scientifically accurate presentation must nevertheless hold two ideas at once: the evidence is sufficiently positive to justify study and use by trained professionals, but is not yet broad enough to render more established psychotherapies obsolete or inferior.

Future outcome measures should include not only symptoms but diagnostic remission, functioning, quality of life and relapse. It is also necessary to clarify the durability of metacognitive changes after sessions end. A very large effect in a small initial study may diminish when treatment is replicated in larger samples and routine services; this phenomenon makes pragmatic replications particularly informative.

Bibliography
1. Normann N et al. The efficacy of metacognitive therapy for anxiety and depression: a meta-analytic review. Depression and Anxiety. 31(5), 2014, 402-411.
2. Normann N et al. The Efficacy of Metacognitive Therapy: A Systematic Review and Meta-Analysis. Frontiers in Psychology. 9, 2018, 2211.
3. Wells A et al. Metacognitive therapy in recurrent and persistent depression: a multiple-baseline study of a new treatment. Cognitive Therapy and Research. 33(3), 2009, 291-300.
4. Wells A et al. Metacognitive therapy in treatment-resistant depression: a platform trial. Behaviour Research and Therapy. 50(6), 2012, 367-373.
5. Wells A. Metacognitive Therapy for Anxiety and Depression. Guilford Press, 2009.
6. Wells A et al. Attention and Emotion: A Clinical Perspective. Lawrence Erlbaum Associates, 1994.
7. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222. 2022; last reviewed 2026.
8. Lam RW et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry. 69(9), 2024, 641-687.
9. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Version 4.0. Washington, DC, 2022.
10. American Psychological Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. Washington, DC: American Psychological Association, 2019.
11. Cuijpers P et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry. 20(2), 2021, 283-293.
12. Cuijpers P et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 22(1), 2023, 105-115.
13. Cuijpers P et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Annals of Family Medicine. 19(3), 2021, 262-270.
14. Cuijpers P et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 13(1), 2014, 56-67.